Otolaryngology
Audio Summaries

[¹⁷⁷Lu]Lu-PSMA-617 in patients with PSMA-positive metastatic androgen pathway modulator-naive/sensitive prostate cancer (PSMAddition): a phase 3 randomised, controlled trial

The PSMAddition trial aimed to evaluate the efficacy and safety of combining [^177Lu]Lu-PSMA-617 with androgen deprivation therapy (ADT) and androgen receptor pathway inhibitors (ARPI) in patients with PSMA-positive metastatic androgen pathway modulator-naive/sensitive prostate cancer. The results indicated that this combination significantly improved radiographic progression-free survival compared to the control group, despite a higher incidence of adverse events, suggesting it may be a viable new treatment option for this patient population.

Iron or Multiple Micronutrient Powder Supplements With Malaria Chemoprevention in Rural Malawian Children: The IRMA Randomized Clinical Trial

The study aimed to determine whether universal iron interventions combined with malaria chemoprevention would enhance cognitive outcomes and safety regarding infection risk in rural Malawian children. The results indicated that neither iron syrup nor iron-containing micronutrient powders improved cognitive scores compared to malaria chemoprevention alone, and both iron interventions did not increase malaria risk. Overall, the findings suggest that these iron interventions did not provide the expected functional benefits in this population.

Duration of Therapeutic Hypothermia After Out-of-Hospital Cardiac Arrest: The ICECAP Randomized Clinical Trial

The ICECAP randomized clinical trial aimed to determine the optimal duration of therapeutic hypothermia at 33 °C for maximizing neurological recovery in comatose survivors of out-of-hospital cardiac arrest. The study found that increasing the duration of cooling did not improve neurological outcomes, with a posterior probability suggesting that a 6-hour duration may be optimal. Overall, no significant differences in secondary outcomes or mortality were observed across varying cooling durations.

Syncope

This article by Rose Anne Kenny addresses the clinical problem of syncope, which is characterized by transient cerebral hypoperfusion and can arise from various mechanisms such as reflex, orthostatic, and cardiac causes. The authors emphasize the importance of accurate diagnosis through thorough history taking, physical examination, and risk stratification to guide targeted testing and management strategies aimed at reducing recurrence and injury risk, particularly in older patients where syncope may present as unexplained falls. The study highlights the necessity of early identification of high-risk features to prevent adverse cardiovascular outcomes.

Classic Hodgkin Lymphoma: A Review

This review aims to provide a comprehensive overview of classic Hodgkin lymphoma (cHL), including its epidemiology, clinical presentation, risk factors, and treatment strategies. The authors highlight that cHL primarily affects younger individuals and that first-line treatment typically involves chemotherapy, with potential additions of radiotherapy and novel agents for certain patient groups. They also discuss the long-term risks faced by survivors, emphasizing the importance of monitoring for secondary malignancies and other complications.

Addition of High-Dose Vitamin D3 to Standard Treatment in Patients With Metastatic Colorectal Cancer: The SOLARIS Randomized Clinical Trial (Alliance A021703)

The SOLARIS trial aimed to determine whether high-dose vitamin D3, when added to standard chemotherapy, improves outcomes in patients with previously untreated metastatic colorectal cancer (mCRC). The study found that high-dose vitamin D3 did not significantly enhance progression-free survival compared to standard-dose vitamin D3, nor did it show improvements in overall survival or response rates. Overall, the addition of high-dose vitamin D3 did not provide clinically meaningful benefits in this patient population.

Multivessel coronary artery bypass grafting via small thoracotomy versus sternotomy (MIST): an investigator-initiated, international, open-label, randomised controlled trial

The authors aimed to compare patient-reported recovery and clinical outcomes between minimally invasive coronary artery bypass grafting (MICS CABG) via small thoracotomy and traditional sternotomy CABG in patients with multivessel coronary artery disease. The study found that MICS CABG significantly improved physical recovery at one month post-surgery without compromising safety through 12 months, suggesting its potential benefit for appropriately selected patients.

Initial HIV Therapy for Adults and Treatment-Associated Weight Gain: The Opti-DOR Randomized Clinical Trial

The study aimed to determine whether a regimen of doravirine, lamivudine, and tenofovir disoproxil fumarate results in less weight gain compared to a regimen of dolutegravir, emtricitabine, and tenofovir alafenamide while maintaining similar levels of viral suppression in ART-naive adults with HIV. The findings indicated that both regimens achieved comparable viral suppression rates at 48 weeks, but the doravirine-based regimen was associated with significantly less weight gain. This suggests that the doravirine regimen may be a preferable option for managing weight-related concerns in individuals starting HIV treatment.

Efficacy and safety of once-weekly subcutaneous zenagamtide, a novel unimolecular GLP-1 and amylin receptor agonist, in type 2 diabetes: a multicentre, randomised, parallel, double-blind, placebo-controlled, dose-finding, phase 2 trial

The authors aimed to evaluate the efficacy and safety of once-weekly subcutaneous zenagamtide, a novel unimolecular GLP-1 and amylin receptor agonist, in adults with type 2 diabetes. The phase 2 trial demonstrated that zenagamtide significantly reduced HbA1c levels compared to placebo across various doses, with a safety profile similar to existing GLP-1 and amylin therapies. Most adverse events were mild to moderate, primarily gastrointestinal, and no deaths occurred during the study.

Dapagliflozin and Acute Kidney Injury Following Cardiac Surgery: A Randomized Clinical Trial

This randomized clinical trial aimed to determine whether initiating dapagliflozin one day prior to elective cardiac surgery could reduce the incidence of acute kidney injury (AKI) within the first week post-surgery. The results showed that dapagliflozin significantly decreased AKI rates compared to placebo (28% vs. 52%), suggesting its potential as a preventive treatment in this patient population. Adverse events such as atrial fibrillation and reoperation rates were similar between the two groups.